Gilead and Compugen enter exclusive license agreement for immunotherapy programme
Betsy Goodfellow | December 20, 2023 | News story | Research and Development | Gilead Sciences, Immunology, License Agreement, compugen, immunology
Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for Compugen’s potential first in class, pre-clinical antibody programme against IL-18 binding protein, including the COM503 drug candidate.
The agreement means Gilead will make an upfront payment of $60m as well as $30m in a near-term milestone payment, with a total deal value of up to $848m, comprising $758m in future development, regulatory and commercial milestones.
Under terms of this agreement, Compugen will remain responsible for the ongoing phase 1 trial of COM503, following which Gilead will have exclusive rights to develop and commercialise the drug candidate.
Anat Cohen-Dayag PhD, president and chief executive officer of Compugen, commented: “We are delighted to enter into this collaboration with Gilead and believe that Gilead’s confidence in our differentiated approach to harness cytokine biology for cancer therapeutics speaks to the quality of our computational discovery capabilities as well as our ability to translate our novel discoveries into investigational drugs in the clinic and we look forward to working together to bring new treatment options to patients. IL-18 is one of the rare cytokines which is naturally inhibited by an endogenous binding protein, presenting a unique opportunity to use a blocking antibody to increase the local concentrations of IL-18 within the tumour where it can potentiate anti-tumour immune responses, thereby potentially overcoming the limitations of systemically administered cytokines.”
Betsy Goodfellow
Related Content
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
The current forms of immunotherapy, how T cell therapy works and what the future holds
Gilead Foundation awards $6.5m in grants to support STEM education
Gilead Sciences has committed over $6.5m in grant funding towards improving science, technology, engineering and …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in …
